

Vertex Pharmaceuticals

Suzetrigine Role in Acute Pain Management

Speaker: Kirubel Hailu, PharmD, BCPS, BCCCP
(Executive Medical Science Liaison with Vertex Pharmaceuticals Pain Program)

Date and time: Saturday, August 8th, from 12:30–1:30 pm
Assigned room name: Merritt Ballroom

RSVP not required.

Seating available on a first-come, first-serve basis.

Suzetrigine (Journavx) is a first-in-class non-opioid analgesic approved by the FDA in January 2025 for the treatment of moderate-to-severe acute pain in adults. It is the first novel analgesic approved in more than 25 years and acts as a highly selective inhibitor of the voltage-gated sodium channel NaV1.8, which is primarily expressed in peripheral sensory neurons.